NCT01724528 - Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies | Biotech Hunter

Enrollment

346

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions

Tumor Lysis Syndrome

Interventions

DRUG

Febuxostat

Standard dose PO (per os) from Day 1 to Day 7 (can be continued up to DAY 9 at investigator's discretion)

DRUG

Allopurinol

Standard dose, low dose or high dose (as per investigator's judgement at the time of randomization) from DAY 1 to DAY 7 (can be continued up to DAY 9 at investigator's discretion)